Skip to main content
. 2018 Apr 4;11:49. doi: 10.1186/s13045-018-0583-7

Fig. 2.

Fig. 2

PFS in KRd patients: ≥CR responders versus <CR responders in overall ASPIRE population. ≥CR, complete response or better; <CR, less than complete response; KRd, carfilzomib, lenalidomide and dexamethasone; PFS, progression-free survival. Based on Simon-Makuch Landmark analysis at 6 months after randomization (intent-to-treat population)